Research Candidates

 
News Articles for Research Candidates top ^
2014/9/8
http://media.marketwire.com/attachments/201402/222912_2014ProgramStamp.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1142565&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for Monster Sponsors Talent Board's 2014 Candidate Experience Awards investment picks
Monster (NYSE: MWW), today launched its Cloud Candidate Relationship Management (CRM) tool to identify and reach qualified candidates with targeted messages and custom recruitment campaigns through one seamless process.
Sign-up for Monster Launches Cloud-Based Recruitment Marketing Platform, Helping Employers Better Connect with Potential Job Candidates investment picks
2014/6/18
Performance Court Official Building Opening: 21-Storey, 360,000 SF Class A LEED Gold Candidate Office Tower Canada NewsWire A Jewel at the Crossroads of Sustainability, Business and the Arts in Downtown Ottawa OTTAWA , June 18, 2014 /CNW/ - When Performance Court was in the conceptual design phase, there was a commitment to "performance" on multiple levels.
Sign-up for Performance Court Official Building Opening: 21-Storey, 360,000 SF Class A LEED Gold Candidate Office Tower investment picks
GSK announces EU regulatory submission for malaria vaccine candidate RTS,S Canada NewsWire LONDON , July 24, 2014 /CNW/ - GSK announced today that it has submitted a regulatory application to the European Medicines Agency (EMA) for its malaria vaccine candidate, RTS,S. The submission will follow the Article 58 procedure, which allows the EMA to assess the quality, safety and efficacy of a candidate vaccine, or medicine, manufactured in a European Union (EU) member state, for a disease recognised by the World Health Organization (WHO) as of major public health interest, but intended exclusively for use outside the EU.
Sign-up for GSK announces EU regulatory submission for malaria vaccine candidate RTS,S investment picks
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate ( PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C.
Sign-up for Pfizer’s Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation investment picks
Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST (MM-020/IFM 07-01)—an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant—have been published in the Sept.
Sign-up for Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine investment picks
http://media.marketwire.com/attachments/201402/222912_2014ProgramStamp.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1126730&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for ManpowerGroup: Global Platinum Sponsor of 2014 Candidate Experience Awards investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus ( Streptococcus pneumoniae ), a major cause of infectious disease-related death globally.
Sign-up for Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004 investment picks
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced its next clinical candidate ARC-AAT, an RNAi therapeutic designed to treat liver disease associated with Alpha-1 antitrypsin deficiency (AATD). The Company is hosting an analyst day today to discuss ARC-AAT and will present preclinical data starting at 12:30 p.m. EDT.
Sign-up for Arrowhead Announces New Clinical Candidate ARC-AAT for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease investment picks
Alkermes plc (NASDAQ: ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four of Alkermes’ pipeline candidates for the treatment of central nervous system (CNS) disorders: aripiprazole lauroxil, ALKS 5461, ALKS 3831 and ALKS 7106.
Sign-up for Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates investment picks
ROCKVILLE, Md., July 24, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that its investigational new drug (IND) for MGD007 has been cleared by the U.S. Food and Drug Administration (FDA) to proceed with the Phase 1 human clinical trial for this drug candidate.
Sign-up for MacroGenics' DART Candidate IND for Colorectal Cancer, MGD007, Cleared to Start Enrolling Patients investment picks
Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, announced that GlaxoSmithKline (NYSE: GSK) has submitted a regulatory application for its malaria vaccine candidate, RTS,S, to the European Medicines Agency (EMA), and it has been accepted for regulatory review.
Sign-up for First Vaccine Candidate for Malaria is Accepted for EU Regulatory Review investment picks
Monster (NYSE: MWW), today announced the launch of Monster Message Center, a new feature to help job candidates simply and efficiently manage communications they receive from employers.
Sign-up for Monster Introduces Communications Hub for Job Candidates investment picks
2014/9/15
Rapid, potent, and durable immunity demonstrated with vaccine candidate (VBI-1501A). Pilot scale (10L) production of VBI-1501A expected to meet Phase I trial release criteria.
Sign-up for New Data Supporting VBI's Prophylactic Cytomegalovirus (CMV) Vaccine Candidate (VBI-1501A) Presented at the 54th ICAAC Conference in Washington, D.C. investment picks
Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company’s universal vaccine candidate against pneumococcus.
Sign-up for Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate investment picks
http://media.marketwire.com/attachments/200911/585051_584784_Logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1136140&ProfileId=051205&sourceType=1 BERKELEY, CA --
Sign-up for Dynavax Reports Second Quarter 2014 Financial Results and Safety and Pharmacodynamic Results for Asthma and Lupus Drug Candidates investment picks
BURLINGTON, Mass., Sept.
Sign-up for Flexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Candidate FX006 investment picks
2014/9/2
TOKYO--Nissan Motor Co.
Sign-up for Nissan to Lose Ghosn Successor Candidate investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Candidates
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Campus  |  Next: Research Capabilities